{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Research Highlights Role of Adjuvant Chemotherapy in Pancreatic Cancer

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify results from a study by the University of Colorado Cancer Center related to the treatment of patients with pancreatic ductal adenocarcinoma (PDAC).
  2. Describe issues related to patient selection for adjuvant chemotherapy (AC) following neoadjuvant chemotherapy (NAC) and surgery for the treatment of a patient with PDAC.

Learning Outcomes

Seventy-five percent of participants will demonstrate knowledge of the role of adjuvant chemotherapy following neoadjuvant chemotherapy and surgery in the treatment of pancreatic ductal adenocarcinoma by achieving a minimum score of 70% on the outcomes-based posttest.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH
  • NM - BON 1.0 CH
  • SC - BON 1.0 CH
  • WV - BOERN 1.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.













Test Code: OT0223
Published: February 2023
Expires: 12/5/2025
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Lindsey Nolan